Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country

MLA

Soon Hin How, et al. “Programmed Death‐ligand 1 Expression and Use of Immune Checkpoint Inhibitors among Patients with Advanced Non‐small‐cell Lung Cancer in a Resource‐limited Country.” Thoracic Cancer, vol. 13, May 2022, pp. 1676–83. EBSCOhost, https://doi.org/10.1111/1759-7714.14442.

APA

Soon Hin How, Lye Mun Tho, Chong Kin Liam, Harissa H. Hasbullah, Gwo Fuang Ho, Ibtisam Muhammad Nor, Mau Ern Poh, Kean Fatt Ho, Muthukkumaran Thiagarajan, Azlina Samsudin, Azza Omar, Choo Khoon Ong, Yong Kek Pang, & Sing Yang Soon. (2022). Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country. Thoracic Cancer, 13, 1676–1683. https://doi.org/10.1111/1759-7714.14442

Chicago

Soon Hin How, Lye Mun Tho, Chong Kin Liam, Harissa H. Hasbullah, Gwo Fuang Ho, Ibtisam Muhammad Nor, Mau Ern Poh, et al. 2022. “Programmed Death‐ligand 1 Expression and Use of Immune Checkpoint Inhibitors among Patients with Advanced Non‐small‐cell Lung Cancer in a Resource‐limited Country.” Thoracic Cancer 13 (May): 1676–83. doi:10.1111/1759-7714.14442.